ES2178152T3 - Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto. - Google Patents

Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto.

Info

Publication number
ES2178152T3
ES2178152T3 ES98904048T ES98904048T ES2178152T3 ES 2178152 T3 ES2178152 T3 ES 2178152T3 ES 98904048 T ES98904048 T ES 98904048T ES 98904048 T ES98904048 T ES 98904048T ES 2178152 T3 ES2178152 T3 ES 2178152T3
Authority
ES
Spain
Prior art keywords
procedures
amino
compound
fluorobenzilamino
etoxicarbonilaminobenceno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98904048T
Other languages
English (en)
Spanish (es)
Inventor
Peter Meisel
Karl-Friedrich Landgraf
Jurgen Schafer
Wilfried Thiel
Matthias Rischer
Alfred Olbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Application granted granted Critical
Publication of ES2178152T3 publication Critical patent/ES2178152T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES98904048T 1997-01-20 1998-01-09 Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto. Expired - Lifetime ES2178152T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19701694A DE19701694A1 (de) 1997-01-20 1997-01-20 Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ES2178152T3 true ES2178152T3 (es) 2002-12-16

Family

ID=7817756

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98904048T Expired - Lifetime ES2178152T3 (es) 1997-01-20 1998-01-09 Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto.

Country Status (30)

Country Link
US (2) US5914425A (en, 2012)
EP (1) EP0956281B1 (en, 2012)
JP (1) JP4138886B2 (en, 2012)
CN (1) CN1125812C (en, 2012)
AR (1) AR015349A1 (en, 2012)
AT (1) ATE222235T1 (en, 2012)
AU (1) AU730776B2 (en, 2012)
BG (1) BG63893B1 (en, 2012)
BR (1) BR9806784A (en, 2012)
CA (3) CA2634811C (en, 2012)
CZ (1) CZ301778B6 (en, 2012)
DE (2) DE19701694A1 (en, 2012)
DK (1) DK0956281T3 (en, 2012)
EG (1) EG21239A (en, 2012)
ES (1) ES2178152T3 (en, 2012)
HU (1) HU227625B1 (en, 2012)
ID (1) ID22645A (en, 2012)
IL (1) IL130384A (en, 2012)
IS (1) IS2115B (en, 2012)
NO (2) NO311642B1 (en, 2012)
NZ (1) NZ336205A (en, 2012)
PL (1) PL195956B1 (en, 2012)
PT (1) PT956281E (en, 2012)
RU (1) RU2186765C2 (en, 2012)
SK (1) SK285303B6 (en, 2012)
TR (1) TR199901674T2 (en, 2012)
TW (1) TW531527B (en, 2012)
UA (1) UA63937C2 (en, 2012)
WO (1) WO1998031663A1 (en, 2012)
ZA (1) ZA98319B (en, 2012)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
JP2010511052A (ja) * 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
EA201170230A1 (ru) * 2008-07-18 2011-08-30 Вэлиант Фармасьютикалс Интернешнл Препарат с модифицированной кинетикой высвобождения и способы его использования
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
WO2011039369A2 (en) 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
SG181827A1 (en) 2010-01-20 2012-07-30 Glaxo Group Ltd Novel retigabine composition
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
CN202095728U (zh) 2010-10-29 2012-01-04 假日集团控股有限公司 行李箱把手
CN102464233A (zh) * 2010-11-18 2012-05-23 江苏邦威机械制造有限公司 一种卧式差速缠丝机用应力发生装置
WO2012098075A1 (en) 2011-01-18 2012-07-26 Glaxo Group Limited Process for the preparation of retigabine
CN102241608A (zh) * 2011-05-12 2011-11-16 天津市汉康医药生物技术有限公司 瑞替加滨化合物及其组合物
WO2013008250A2 (en) * 2011-07-01 2013-01-17 Dr.Reddys Laboratories Limited. Crystalline form of retigabine and processes for mixture of retigabine crystalline modifications
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
USD696019S1 (en) 2011-10-21 2013-12-24 Travelpro International Inc. Handle for luggage
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US20140350285A1 (en) * 2012-01-30 2014-11-27 Symed Labs Limited Novel polymorphs of n-[2-amino-4-(4-fluorobenzylamino)-phenyl] carbamic acid ethyl ester and processes thereof
CN103373941B (zh) * 2012-04-11 2016-08-17 浙江九洲药物科技有限公司 瑞替加滨及其中间体的制备方法
WO2013179298A2 (en) * 2012-04-23 2013-12-05 Cadila Healthcare Limited A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
WO2014023270A1 (en) 2012-08-09 2014-02-13 Zentiva, K.S. Salts or co-crystals of ethyl n-[2-amino-4-[(4-fluorophenyl)methylamino]-phenyl]carbamate
CN102964273B (zh) * 2012-12-06 2014-04-02 北京英科博雅科技有限公司 瑞替加滨的新晶型f及其制备方法
USD773819S1 (en) 2015-05-27 2016-12-13 Travelpro Products, Inc. Handle for luggage
KR20220080119A (ko) 2019-10-10 2022-06-14 제논 파마슈티칼스 인크. 선택적 칼륨 채널 조절제의 고체 상태 결정성 형태
CR20220250A (es) 2019-11-08 2022-08-19 Xenon Pharmaceuticals Inc Métodos para el tratamiento de trastornos depresivos
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3917113A1 (de) * 1989-05-26 1990-11-29 Schwarzkopf Gmbh Hans Verfahren zur selektiven herstellung von n(pfeil hoch)4(pfeil hoch)-substituierten 1,4-diamino-2-nitrobenzolen
GB8921792D0 (en) * 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung

Also Published As

Publication number Publication date
EG21239A (en) 2001-03-31
NZ336205A (en) 2000-01-28
TW531527B (en) 2003-05-11
JP4138886B2 (ja) 2008-08-27
WO1998031663A1 (de) 1998-07-23
EP0956281A1 (de) 1999-11-17
IS5098A (is) 1999-06-29
UA63937C2 (uk) 2004-02-16
SK285303B6 (sk) 2006-10-05
CN1243506A (zh) 2000-02-02
CZ250899A3 (cs) 1999-11-17
HUP0000944A3 (en) 2000-10-30
CA2278201C (en) 2009-06-16
US5914425A (en) 1999-06-22
PL335647A1 (en) 2000-05-08
AU6208198A (en) 1998-08-07
PT956281E (pt) 2002-12-31
DK0956281T3 (da) 2002-11-04
ATE222235T1 (de) 2002-08-15
NO2011017I1 (no) 2011-09-26
BR9806784A (pt) 2000-05-02
IS2115B (is) 2006-06-15
DE59805186D1 (de) 2002-09-19
EP0956281B1 (de) 2002-08-14
PL195956B1 (pl) 2007-11-30
HUP0000944A2 (hu) 2000-09-28
CA2632585C (en) 2010-08-24
RU2186765C2 (ru) 2002-08-10
CA2278201A1 (en) 1998-07-23
CA2634811C (en) 2012-11-20
TR199901674T2 (en, 2012) 1999-10-21
SK95699A3 (en) 2000-03-13
JP2001508077A (ja) 2001-06-19
CN1125812C (zh) 2003-10-29
US6538151B1 (en) 2003-03-25
NO2011017I2 (no) 2013-04-02
CA2634811A1 (en) 1998-07-23
HK1024230A1 (en) 2000-10-05
BG63893B1 (bg) 2003-05-30
DE19701694A1 (de) 1998-07-23
CZ301778B6 (cs) 2010-06-23
ID22645A (id) 1999-12-02
NO993452L (no) 1999-07-13
NO311642B1 (no) 2001-12-27
HU227625B1 (en) 2011-09-28
NO993452D0 (no) 1999-07-13
AR015349A1 (es) 2001-05-02
IL130384A0 (en) 2000-06-01
AU730776B2 (en) 2001-03-15
IL130384A (en) 2003-02-12
BG103657A (en) 2000-02-29
ZA98319B (en) 1998-05-07
CA2632585A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
ES2178152T3 (es) Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto.
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
AR028948A1 (es) Compuestos novedosos
ES2170460T3 (es) Compuestos triaromaticos, composiciones que los contienen y utilizaciones.
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ES2196377T3 (es) Derivados de naftiridina.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
AR005053A1 (es) Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
ES2094380T3 (es) Nuevos pirazolilpirazoles sustituidos, procedimientos para su preparacion, asi como compuestos intermedios, y su uso como herbicidas.
AR025756A1 (es) Un compuesto de acido sustituido, composiciones y combinaciones farmaceuticas que lo comprenden y su uso para la preparacion de medicamentos
ES2142034T3 (es) Compuestos biaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
HN2002000300A (es) Nuevos derivados de piperazina
CO5390079A1 (es) Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
ES2119326T3 (es) Compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.